Recognition of distinct cross-reactive virus-specific CD8+ T cells reveals a unique TCR signature in a clinical setting
Research output: Contribution to journal › Article › Research › peer-review
Human CMV still remains problematic in immunocompromised patients, particularly after solid organ transplantation. CMV primary disease and reactivation greatly increase the risks associated with incidences of chronic allograft rejection and decreased survival in transplant recipients. But whether this is due to direct viral effects, indirect viral effects including cross-reactive antiviral T cell immunopathology, or a combination of both remains undetermined. In this article, we report the novel TCR signature of cross-reactive HLA-A*02:01 (A2) CMV (NLVPMVATV [NLV])-specific CD8 + T cells recognizing a specific array of HLA-B27 alleles using technical advancements that combine both IFN-? secretion and multiplex nested RT-PCR for determining paired CDR3a/b sequences from a single cell. This study represents the first evidence, to our knowledge, of the same A2-restricted crossreactive NLV-specific TCR-a/? signature (TRAV3TRAJ31-TRBV12- 4TRBJ1-1) in two genetically distinct individuals. Longitudinal posttransplant monitoring of a lung transplant recipient (A2, CMV seropositive) who received a HLA-B27 bilateral lung allograft showed a dynamic expansion of the cross-reactive NLV-specific TCR repertoire before CMV reactivation.